CommercialDocumentationMedium impact
08.01.84f, Efgartigimod alfa - fcab (Vyvgart)
Independence Blue Cross·Neurology, Internal Medicine·Medical Policy
Effective date
Oct 26, 2026
We identified it
Jul 28, 2026
Summary
Policy 08.01.84f updates medical necessity criteria and medical coding requirements for Efgartigimod alfa - fcab (Vyvgart), a monoclonal antibody immunosuppressant. Changes take effect October 26, 2026, requiring billing teams to update authorization protocols and coding practices for this medication.
Action Required
By October 26, 2026: Billing team must review the complete policy text at the provided URL to identify specific medical necessity criteria updates and coding changes for Vyvgart claims. Update billing system validation rules, prior authorization workflows, and claim submission guidelines accordingly. Ensure providers document medical necessity per new criteria. Contact the payer (IBX) if specific code mappings or authorization requirements are unclear. Claims submitted after the effective date that do not meet updated medical necessity criteria or use incorrect coding will be denied.